文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前列腺癌淋巴结阳性RTOG淋巴结放疗后PET/CT淋巴结复发模式

Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-02-26

回顾性分析2008-2018年NKI-AVL接受根治性外照射的前列腺癌淋巴结阳性患者42例,生化复发时行PSMA或胆碱PET/CT,35例阳性,野内淋巴结复发仅3例,野外14例且12例位于 elective 野上缘,6例为唯一失败部位,提示扩大 elective 野可能改善无复发生存。

要点

  • RTOG-based elective nodal fields 野内淋巴结复发少见(n=3),野外复发更常见(n=14)。
  • 野外淋巴结复发中12例位于 elective nodal field 上缘,6例为唯一可检测失败部位。
  • 扩大 elective fields 以包含腹主动脉分叉可能延长无复发生存,但需权衡毒性。

核心结论

  • 当前RTOG-based淋巴结野对前列腺癌淋巴结阳性患者提供良好野内肿瘤控制,但频繁野外淋巴结复发提示遗漏微观病变。
  • 扩大 elective fields 以包含腹主动脉分叉可能延长无复发生存,但需未来研究评估获益是否超过额外毒性。

研究设计与样本

  • 回顾性分析2008至2018年NKI-AVL所有接受根治性外照射的前列腺癌淋巴结阳性患者数据。
  • 42例生化复发时接受PSMA(28例)或胆碱(14例)PET/CT,记录复发位置并与外照射野相关。

主要发现

  • 35例(83%)PET/CT阳性。
  • 首次阳性扫描时17例有淋巴结转移,部分合并局部复发或远处病变。
  • 野内淋巴结复发少见(n=3),野外淋巴结复发更常见(n=14),其中多数(n=12)位于 elective nodal field 上缘。
  • 这些淋巴结为6例患者(14%)唯一可检测失败部位。

临床怎么用

  • 对前列腺癌淋巴结阳性患者行RTOG-based elective nodal放疗后,生化复发时应关注 elective 野上缘及腹主动脉分叉区域的淋巴结复发。
  • 考虑扩大 elective nodal fields 以包含腹主动脉分叉时,需权衡潜在无复发生存获益与额外毒性。

局限性

  • 回顾性研究,样本量有限(42例)。
  • PET/CT显像剂包括PSMA和胆碱,两者检测效能可能存在差异。
  • 未报告扩大 elective fields 后的毒性数据及生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Biochemical failure after external beam radiotherapy (RT) for node-positive prostate cancer (PCN+) frequently involves nodal recurrences, in most cases out of field. This raises the question if current RTOG-based elective nodal fields can still be considered optimal. Modern diagnostic tools like PSMA PET/CT and choline PET/CT can visualize nodal recurrences with unprecedented accuracy. We evaluated recurrence patterns on PET/CT after RT for PCN+, with the aim to explore options for improved nodal target definition. METHODS AND MATERIALS: Data of all patients treated with curative intent EBRT for PCN+ in NKI-AVL from 2008 to 2018 were retrospectively reviewed. EBRT comprised 70 Gy to the prostate or 66-70 Gy to the prostate bed, 60 Gy to involved nodes, and 52,5-56 Gy (46 Gy EQD2) to RTOG-based elective nodal fields, in 35 fractions. Locations of recurrences on PET/CT were noted, and nodal locations were correlated with the applied EBRT fields. RESULTS: 42 patients received PSMA (28) or choline (14) PET/CT at biochemical recurrence. 35 patients (83%) had a positive scan. At their first positive scan 17 patients had nodal metastasis, in some cases together with a local recurrence or distant disease. In-field nodal recurrences were uncommon (n = 3). Out-field nodal recurrences occurred more frequently (n = 14), with the majority (n = 12) just above the elective nodal field. These nodes were the single area of detectable failure in 6 patients (14%). CONCLUSIONS: Current RT with RTOG-based nodal fields for PCN+ provides good in-field tumour control, but frequent out-field nodal recurrences suggest missed microscopic locations. Expanding elective fields to include the aorta bifurcation may prolong recurrence-free survival. Future research must address whether the potential benefits of this strategy outbalance additional toxicity.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liskamp CP, Donswijk ML, van der Poel HG, et al. Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer. Clin Transl Radiat Oncol. 2020. PMID: 32154392. doi:10.1016/j.ctro.2020.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。